Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cemiplimab · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cemiplimab in combination with RP1 | EXPERIMENTAL | Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks |
| Cemiplimab | ACTIVE_COMPARATOR | Cemiplimab administered intravenously as a single therapy every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Cemiplimab | DRUG | Cemiplimab administered intravenously |
| RP1 | BIOLOGICAL | RP1 administered intratumorally |
Key Inclusion Criteria: * Histologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma * Patients with locally advanced disease who are not suitable candidates for surgical or radiological treatment of lesions or have refused those treatments * At least 1 lesion that is...
Cemiplimab is being studied for the treatment of Cutaneous Squamous Cell Carcinoma, including advanced and metastatic forms of the disease. It is an investigational therapy currently in Phase 2 clinical development for this indication.
Cemiplimab is a monoclonal antibody, classified as a -mab (antibody) modality. It is being evaluated in combination with another agent for the treatment of advanced squamous skin cancer.
Cemiplimab is being developed by Replimune Group, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol REPL.
Cemiplimab is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
Cemiplimab is being studied in a Phase 2 clinical trial with the identifier NCT04050436. This trial evaluates Cemiplimab alone and in combination with RP1 in treating advanced squamous skin cancer, with an enrollment of 231 participants.
Yes, the Phase 2 trial of Cemiplimab is randomized and active-controlled. The study is not double-blinded and does not use a biomarker-selected patient population.